Available online on 15 Dec, 2023 at https://ijdra.com/index.php/journal

International Journal of Drug Regulatory Affairs

Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with RAPS & Delhi Pharmaceutical Sciences & Research University

Review Article

Open Access

Navigating the Regulatory Landscape: Key Trends Shaping Today's Regulatory Affairs Environment

Bidhya Sharma[a,*], Anmol Gurung[a], Prena Pradhan[a], Depesh Darjee[a], Naveen Kumar Kotla[b]

[a] Government Pharmacy College, Sajong, Rumtek, East Sikkim, India.

[b] Monash University, Parkville, Melbourne, Australia.

Abstract

Regulatory Science, positioned at the intersection of Science, policy, and law, is essential for safeguarding public health and ensuring the safety and effectiveness of products and practices. It spans various sectors, including pharmaceuticals, medical devices, food and agriculture, environmental protection, and emerging technologies. It faces challenges and opportunities such as rapid technological advancements, global market globalization, and complex scientific discoveries.

This review paper examines current trends and future directions in Regulatory Aspects within the Pharmaceutical World. It explores how regulatory authorities address challenges and delves into the historical development of pharmaceutical regulation globally. The paper also explores innovative approaches and technologies influencing the regulatory processes, investigates future directions in regulation, and proposes recommendations for the future of pharmaceutical regulations.

In conclusion, regulatory Science, with its rich history, holds promise for a bright future. Adapting to technological advancements, embracing collaborative approaches, and investing in research and education are crucial for navigating the complexities of the modern world. Regulatory Science will continue to play a vital role in safeguarding public health and fostering innovation.

Keywords: Regulatory Science, public health, pharmaceutical regulation, Regulatory landscape, Emerging trends, Collaborative approaches, Innovation in Regulatory Science, Artificial intelligence (AI) in regulatory processes.

Article Info: Received 23 Nov 2023; Review Completed 14 Dec 2023; Accepted 15 Dec 2023

Cite this article as:
Sharma B, Gurung A, Pradhan P, Darjee D, Kotla NK. Navigating the Regulatory Landscape: Key Trends Shaping Today's Regulatory Affairs Environment. Int J Drug Reg Affairs [Internet]. 2023 Dec 15 [cited 2023 Dec 15]; 11(4):87-92. Available from:
http://ijdra.com/index.php/journal/article/view/639

DOI: 10.22270/ijdra.v11i4.639
*Corresponding author

1. Introduction

In our rapidly evolving scientific landscape, the Food and Drug Administration (FDA) faces the intricate task of safeguarding public health by employing scientifically sound regulatory activities, a challenge that persists. (1) Regulatory processes in the pharmaceutical industry, vital for ensuring the safe and effective use of medicines, come at a considerable cost and can lead to delays in launching new and improved treatments. The accelerating pace of advancements in Science and technology, coupled with the diminishing boundaries between traditional and emerging healthcare providers, underscores the pressing need for new regulatory frameworks. (2) Establishing greater clarity on how these changes will impact the relationships between regulators, industry players, patients, and other stakeholders is imperative. The fundamental goal of regulatory activities remains the protection of the public from harmful medicinal products, ensuring approval for those demonstrating a favourable benefit-risk balance. (3)

A comprehensive definition of pharmaceutical regulation, as proposed by John G. Francis, states that regulation occurs when the state constrains private activity to promote the public interest. (4) The term 'regulatory science' has an unclear origin. Still, it is believed to have been first used in the 1970s when the newly established US Environmental Protection Agency (EPA) had to make decisions based on limited and sometimes non-existent scientific data. (5) Later, regulatory Science was defined as the body of scientific and technical knowledge serving regulatory decision-making. (6)

Typically, regulatory affairs involve the reactive application of established regulatory concepts to specific drug development or the drug life cycle, primarily focusing on compliance with regulations. (7) In contrast, regulatory Science is characterized as the proactive analysis of regulatory concepts and the pursuit of their evolution in alignment with ongoing scientific advancements. The

development and optimization of regulations are the central themes of regulatory Science.

According to the US Food and Drug Administration, regulatory Science is the Science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products. The European Medicines Agency (EMEA) defines regulatory Science as a range of scientific disciplines applied to the quality, safety, and efficacy assessment of medicinal products, informing regulatory decision-making throughout medicine's lifecycle. (8)

Regulatory science plays a vital role in the pharmaceutical sector by ensuring pharmaceutical products' safety, efficacy, and quality. It encompasses scientific and technical activities that inform the development, evaluation, and regulation of drugs, biologics, and medical devices. Today, regulatory Science is recognized as a crucial component of the pharmaceutical industry, serving as a significant field that aims to integrate new scientific discoveries, techniques, technologies, and knowledge into society effectively. (9) Regulatory Science's first contribution is providing data production tools. A prominent example highlighting the importance of tools is the drug thalidomide, whose teratogenicity was discovered through testing on sensitive animals like rabbits. This underscores the crucial role of trustworthy tools in regulatory Science. Recent years have witnessed growing interest in novel tools such as biomarkers, adaptive designs, and model-based systems to enhance the effectiveness of drug development. (10) Data evaluation stands out as a primary responsibility of regulatory Science. When assessing data, considerations extend to a drug's potential effects on patients or society, determining the relevance of the information. Regulatory Affairs (RA) is the international interface between pharmaceutical businesses and drug regulatory authorities. (11) Regulatory Affairs professionals oversee drug submissions, ensuring adherence to the Food and Drug Act, regulations, guidelines, and policies. They navigate legal and scientific constraints, collecting, evaluating, and presenting registration documents to regulatory agencies for product marketing authorization.. (12)

1.1. Evolution of Regulatory Science/Affairs

Modern medicine regulation originated after 19th-century advancements in life sciences, laying the groundwork for contemporary drug research and the post-World War II emergence of the pharmaceutical industry. (13) The roots of present-day pharmaceutical oversight in the USA trace back to the Mexican-American War (1846-1848), where the import of substandard medications for ailments like malaria and cholera led to detrimental consequences for American troops. To address this, the Import Drug Act of 1848 became the inaugural law regulating medicine imports, mandating the inspection of drugs for quality and purity upon entry at ports. (14)

In 1901, a vaccine tragedy occurred, with a contaminated Diphtheria antitoxin from the St. Louis city health department causing 14 deaths and nine more in Camden, New Jersey. This led to the enactment of the Biologics Control Act of 1902. (15) In 1938, over 100 people died due to diethylene glycol used in mixing a sulfanilamide drug. The Food, Drug, and Cosmetic Act of 1938 was enacted to oversee the safety of medicines, making premarketing approval mandatory for all new drugs. (16) The Durham-Humphrey Amendment 1951 categorized medicines as Over-The-Counter (OTC) or Prescription drugs. (17) Significant changes occurred with the Kefauver-Harris Drug Amendments 1962, mandating efficacy, safety data, Good Manufacturing Practices (GMPs), and prior FDA Marketing Authorization Approval for Western Europe-based drugs. (18)

In India, after World War I, the demand for drugs increased, leading to the influx of cheap and substandard drugs into the market, akin to the situation in the USA during the Mexican-American War.

a) 1900-1960: To control cheap drugs, the government passed the Poisons Act of 1919, regulating the possession and sale of poisons, safe custody, labelling, packaging, and inspection. Acts and rules passed during this era include the Drugs and Cosmetics Act of 1940, Drugs and Cosmetics Rules of 1945, Pharmacy Act of 1948, Drugs and Magic Remedies (Objectionable Advertisements) Rules of 1955, and Drugs Prices Control Order of 1955 (DPCO). (19)

b) 1960-1970: The Indian pharmaceutical industry faced early growth, limited research and development, high import dependency, high drug costs, and low market availability due to multinational companies dominating market share—the Indian Patent Act of 1970 limited patent protection to manufacturing processes and methods of a drug substance.

c) 1980-1990: The industry invested in API process development and created production infrastructure—the Narcotic Drugs and Psychotropic Substances Act of 1985 regulated the operation of narcotic drugs and substances.

d) 1990-2000: The pharmaceutical industry observed rapid expansion in the domestic market, globalization, and increased research activity. India joined the Paris Cooperation Treaty (PCT) in 1999 and implemented product patents effective January 1, 2005.

e) 2000-2010: This period marked the Innovation and Research era, with increased research activity, patenting of drug formulas, processes, and indications, as well as company mergers. The Patent Amendment Act of 2005 allowed manufacturers to market a Black Box Application if they invested significant time and effort in manufacturing and marketing the product before January 1, 2005. Compulsory licenses were granted for drug product manufacturing and export to countries with insufficient manufacturing capacity for public health issues. (20)

1.2. Current Megatrends in Pharmaceutical Regulation

Megatrends are global trends with the potential to unfold over several years and bring substantial transformative impacts on society. (21) The Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) has identified global megatrends, including adapting to diving into digital, changing environments, leaning cleaner and greener, unlocking health, geopolitical shifts, autonomous systems, and the human dimension. (22)

a) Diving into Digital:

The "Diving into digital" megatrend is reshaping pharmaceutical regulatory aspects with key impacts: i. Digital Health Technologies: Adopting mobile health apps, telemedicine, and remote monitoring necessitates a regulatory focus on safety, efficacy, and privacy. ii. Data Privacy and Security: Stricter regulations, like GDPR, address privacy concerns linked to digital health technologies. iii. Real-world Data and Evidence: Digital tools enhance regulatory decision-making by collecting real-world data from diverse sources. iv. Clinical Trials and Digitalization: Regulatory validation and updated guidelines are essential for the digital transformation of clinical trials. v. Pharmacovigilance and Digital Surveillance: Digital technologies enable real-time monitoring of adverse drug reactions, boosting pharmacovigilance. vi. Regulatory Innovation and Adaptation: Regulatory frameworks must innovate and adapt to accommodate the integration of digital health technologies. (23)

b) Adapting to a Changing Environment:

The "Change in Environment" megatrend encompasses factors like climate change and evolving public health concerns, impacting regulatory aspects:

- Climate Change Adaptation: Regulations must address changing disease patterns resulting from climate change.
- Emerging Diseases and Pandemics: Regulatory changes require contingency plans and streamlined approval processes for pharmaceutical companies.
- Environmental Monitoring and Reporting: Mandated monitoring and reporting of environmental impacts from pharmaceutical activities ensure transparency.
- Sustainable Supply Chains: Regulatory approval emphasizes sustainable and ethical practices for pharmaceutical supply chains.
- Public Health and Environmental Awareness: Public concerns prompt stricter regulations and increased public participation. (24)

c) Unlocking the Health Imperative:

The "Unlocking the health imperative" megatrend focuses on shifting healthcare paradigms to proactive measures, impacting regulatory aspects:

- Precision Medicine and Regulatory Frameworks: Regulatory adaptation for personalized therapies involving genetic testing and biomarkers is needed.
- Digital Health and Regulatory Oversight: Product development, cybersecurity, and data management guidelines are established.
- Health Technology Assessment (HTA) and Value-based Pricing: Assessment of healthcare interventions influences regulatory decisions and pricing strategies.
- Pharmacovigilance and Early Detection of Adverse Events: Robust systems are needed to detect and monitor adverse events in pharmaceutical products early.
- Patient Engagement and Regulatory Decision-making: Patient input is recognized as crucial for a patient-centric approach and improved access to innovative treatments.
- Regulatory Flexibility for Innovation: Adaptable frameworks support innovative approaches like accelerated pathways and conditional approvals. (25)

d) Geopolitical Shifts:

The "Geopolitical Shift" megatrend involves changes in global political dynamics, trade relationships, and regulatory frameworks, impacting regulatory aspects:

- Trade and Market Access: Requirements for compliance change with geopolitical shifts affecting pharmaceutical market access.
- Regulatory Convergence and Divergence: Geopolitical shifts influence the harmonization or divergence in regulatory measures. (26)
- Intellectual Property (IP) Protection: Changes in IP protection affect pharmaceutical product rights and regulatory aspects.
- Supply Chain Resilience and Security: Emphasis on supply chain resilience and security requires regulatory attention.
- Regulatory Compliance and Data Sharing: Changes in geopolitical landscapes affect regulatory compliance, data sharing, and safety monitoring.
- Market Surveillance and Enforcement: Geopolitical shifts influence regulatory agencies' focus on market surveillance and enforcement activities.
- Collaboration and International Standards: Geopolitical changes can impact international collaboration and alignment of regulatory standards and hinder common approaches. These megatrends highlight the evolving landscape of the pharmaceutical industry and the dynamic regulatory challenges that must be addressed for continued progress and public health protection. (27)

2. Methodology

The scoping review methodology was employed to thoroughly investigate the history, current status, and future directions of regulatory aspects in the pharmaceutical world. A scoping review aims to map existing literature, identify key concepts, and provide an overview of available evidence on a specific topic. Unlike systematic reviews, which focus on specific research questions and conduct detailed quality assessments, scoping reviews aim to provide breadth rather than depth of analysis.

a) Search Strategy: A systematic search strategy was developed to retrieve relevant literature comprehensively. Electronic databases, including Google Scholar, PubMed, Springer Link, JETIR, and Wiley Online Library, were utilized. The search terms

and phrases included "Regulatory Science," "Evolution of Regulation," "Current Megatrends," and "Future Aspects," along with their variants.

b) Inclusion and Exclusion Criteria: Studies were included if they met the following requirements: (a) they addressed the evolution of regulatory sciences in Pharmaceuticals; (b) they provided empirical data or theoretical insights into regulatory aspects of pharmaceuticals; (c) they were published in English-language peer-reviewed journals; and (d) they were freely accessible in full text.

c) Data Extraction and Analysis: The selected studies extracted vital information and insights related to regulatory Science in the pharmaceutical industry. This involved identifying the history, current scenario, future direction, and challenges of regulatory Science.

d) Interpretation and Discussion: The findings were interpreted and discussed in the context of the objectives of the review paper. The implications of regulatory science/affairs for pharmaceutical firms were analyzed.

The scoping review methodology facilitated a comprehensive exploration of the literature, ensuring a broad understanding of the pharmaceutical world's history, current status, and future directions of regulatory aspects. While not providing an exhaustive analysis of each study, the methodology allowed for a systematic and structured approach to map existing evidence and identify key insights. This approach ensures transparency, reproducibility, and rigour in the scoping review process.

3. Results and Discussion

Digital Disruptions: Leveraging Real-World Evidence (RWE) and AI in the Regulatory Process

Digital disruption impacts every stage of the drug development process, from early-stage target molecule identification to regulatory approvals. The integration of artificial intelligence (AI), big data, and machine learning (ML) in regulatory processes is facilitating real-time regulation, incorporating real-world evidence (RWE), considering patient preferences, and promoting global harmonization among regulatory authorities. (28) The US FDA defines RWE as data on patient health status and healthcare delivery collected from various sources, including electronic health records, claims, and patient-generated data. RWE generates real-world evidence, providing valuable insights into healthcare for research, patient identification, trend analysis, and formulating robust research questions. (29, 30)

Regulatory Aspects of RWE

Traditional pharmacovigilance methods, such as periodic safety update reports (PSURs), have been supplemented by new digital technologies like the Sentinel Initiative, a USFDA surveillance system. Regulators acknowledge the importance of RWE in decision-making and aim to establish paths for integrating data from multiple sources. The USFDA introduced the Advancing Real-World Evidence program 2022 to enhance RWE-based approaches for labelling claims and post-approval study requirements. (31-33)

Challenges in Regulatory Aspects of RWE

RWE poses challenges related to data quality, standardization, methodological limitations, privacy, and regulatory acceptance. Data quality and reliability issues arise due to variations in data from diverse sources, impacting completeness and accuracy. Standardization and data integration challenges arise from harmonizing data from different healthcare systems. Methodological limitations include biases in RWE studies, impacting validity. Privacy and ethical considerations involve ensuring ethical practices in obtaining and analyzing real-world data. Regulatory acceptance and validation challenges involve developing clear guidelines for incorporating RWE into decision-making while ensuring evidence robustness. (34-38)

Leveraging AI in the Regulatory Process

AI is gaining attention in regulatory processes for its efficiency, effectiveness, transparency, and automation. In drug discovery and development, AI revolutionizes processes by predicting drug candidates and analyzing biological, chemical, and clinical data. AI aids regulatory compliance, pharmacovigilance, quality control, and regulatory intelligence. (39-44) Regulatory aspects of AI involve frameworks like the US FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) qualification program. AI's role extends to clinical applications, with numerous regulatory approvals for AI/ML-enabled medical devices. (45-47)

Rapidly Evolving Therapeutic Landscape

The therapeutic landscape is rapidly advancing with innovations like nanotechnology, biologics, precision medicine, ATMPs, digital health technologies, mRNA-based therapeutics, and 3D-printed medicines/devices. Regulatory challenges arise in adapting frameworks for novel therapies, ensuring safety, efficacy, and quality. Nanotechnology's impact on FDA-regulated products necessitates clear regulatory definitions. Biologics and biosimilars require specialized regulatory frameworks, while precision medicine demands updated guidelines and evidence standards. ATMPs present challenges in balancing patient safety and innovation. Digital health technologies require regulatory oversight for privacy and effectiveness. mRNA-based therapeutics and 3D-printed medicines/devices need tailored regulatory pathways and comprehensive validation.

The pharmaceutical regulatory landscape is evolving to meet the demands of a rapidly changing industry, incorporating digital advancements and adapting frameworks for innovative therapies. (48-62)

4. Discussion

This review thoroughly explores the historical evolution, current landscape, and future directions of pharmaceutical regulations. It traces the progression of drug regulations, emphasizes the role of international harmonization, and underscores the vital role of regulatory agencies in ensuring drug safety and efficacy. The analysis addresses

challenges and emerging trends, including the impact of technology and globalization on the pharmaceutical supply chain. Looking ahead, key directions for pharmaceutical regulations are identified, emphasizing the importance of staying updated, compliance efforts, and collaborative stakeholder engagement. The project highlights the critical role of regulatory practices in maintaining public health, ensuring patient safety, and fostering innovation in the pharmaceutical industry.

5. Conclusion

In conclusion, Regulatory Science, with its resilient history, is poised for an impactful future. Embracing technological advancements, fostering collaboration, and sustaining investment in research and education are vital to fortifying the field amid evolving challenges. As a crucial catalyst for innovation and a guardian of public health, Regulatory Science integrates scientific expertise, adaptive frameworks, and global collaboration to ensure responsible and safe deployment of emerging technologies. Positioned as a beacon in this era of rapid progress, Regulatory Science actively shapes change, emphasizing excellence and a forward-looking approach to align Science and technology with the imperative of public welfare. The promise of a brighter future lies in its adaptability, collaboration, and unwavering dedication to knowledge and public good.

Acknowledgments

We would like to express our sincere gratitude to IJDRA Journal for publishing our work.

Financial Disclosure statement

The author received no specific funding for this work.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

1. Mahaparale Sonali, Bhhakti R. Desai. Role and overview of drug regulatory affairs in the pharmaceutical industry with implementation. World Journal of Pharmaceutical Research. 2015;7(7):201-215.
2. Francis JG. The politics of regulation: a comparative perspective. Oxford: Blackwell; 1993:105.
3. Callréus T, Schneider CK. The emergence of regulatory Science in pharmaceutical medicine. Pharmaceutical Medicine. 2013;27:345-351.
4. Callréus T. The precautionary principle and pharmaceutical risk management. Drug Safety. 2005;28:465-471.
5. European Medicines Agency. Draft guideline on similar biological medicinal products 2003; CHMP/437/04Rev1. [Internet]. EMA; 2013 [cited 2023 Nov 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978
6. Molins R. Regulatory Science and Regulatory Affairs. Journal of Regulatory Science. 2017;5(2):Editorials.
7. Uyama Y. The importance of a regulatory science approach for better pharmaceutical regulation. Translational and Regulatory Sciences. 2019;1(1):8-11.
8. Kawade D, Sahastrabuddhe M, Dubey M, et al. An overview of regulatory affairs in pharmaceutical industries. Journal of Emerging Technologies and Innovative Research (JETIR). 2021;8(6).
9. Rägo L, Santoso B. Drug regulation: history, present and future. In: International Textbook of Clinical Pharmacology. 2008;2:65-77.
10. Worthen DB. Pharmaceutical legislation: a historical perspective. International Journal of Pharmaceutical Compounding. 2006;10(1):20.
11. Coleman TS. Early Development in the Regulation of Biologics. JSTOR. 2016;71(4).
12. Ballentine CS. Sulfanilamide disaster. FDA Consumer Magazine. 1981;5.
13. Reilly G. The FDA and Plan B: The Legislative History of the Durham-Humphrey Amendments and the Consideration of Social Harms in the Rx-OTC Switch. 2006. Available from: https://dash.harvard.edu/bitstream/handle/1/8965550/Reilly06.html
14. Meadows M. Promoting safe and effective drugs for 100 years. FDA Consumer Magazine. 2006;40(1).
15. Rahalkar H. Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs. Pharmaceutical Regulatory Affairs: Open Access. 2012; S11-002. doi: 10.4172/2167-7689.S11-0.
16. Zoon KC, Yetter RA. The Regulation of Drugs and Biological Products by the Food and Drug Administration. In: Principles and Practice of Clinical Research. 2012;79-90.
17. Artuso F, Guijt I. Global Megatrends: Mapping the forces that affect us all; 2020.
18. Naughtin C, Hajkowicz S, Schleiger E, Bratanova A, Cameron A, Zamin T, Dutta A. Our future world: Global megatrends impacting the way we live over coming decades; 2022.
19. Zhang D, Mishra S, Brynjolfsson E, Etchemendy J, Ganguli D, Grosz B, Perrault R. The AI index 2021 annual report. arXiv preprint arXiv:2103.06312.
20. Chen RJ, Lu MY, Chen TY, Williamson DF, Mahmood F. Synthetic data in machine learning for medicine and healthcare. Nature Biomedical Engineering. 2021;5(6):493-497.
21. EC. Europe fit for the digital age: Commission proposes new rules and actions for excellence and trust in artificial intelligence. Brussels, Belgium: European Commission; 2021.
22. Suddendorf T, Busby J. Making decisions with the future in mind: Developmental and comparative identification of mental time travel. Learning and Motivation. 2005; 36(2):110-125.
23. Marinus R, Mofid S, Mpandzou M, Kühler TC. Rolling reviews during COVID-19: the European Union experience in a global context. Clinical Therapeutics. 2022;44(3):352-363.
24. Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Medical Research Methodology. 2022;22(1):287.
25. Dagenais S, Russo L, Madsen A, Webster J, Becnel L. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clinical Pharmacology & Therapeutics. 2022;111(1):77-89.
26. Riskin D. How real-world evidence is shaping the future of healthcare [Internet]. Forbes; 2021 [cited 2023 Nov 3]. Available from: https://www.forbes.com/sites/forbestechcouncil/2021/11/18/how-real-world-evidence-is-shaping-the-future-of-healthcare/?sh=4519a7627fe3. Accessed June 6, 2022.
27. Tau N, Shepshelovich D. Assessment of data sources that support US Food and Drug Administration medical devices safety communications. JAMA Internal Medicine. 2020;180(11):1420-1426.
28. Maruszczyk K, Aiyegbusi OL, Torlinska B, Collis P, Keeley T, Calvert MJ. Systematic review of guidance for the

collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy. Journal of Patient-Reported Outcomes. 2022;6(1):1-11.
29. US Food and Drug Administration. Advancing real-world evidence program [Internet]. FDA; 2022 [cited 2023 Nov 3]. Available from: https://www.fda.gov/drugs/developmentresources/advancing-real-world-evidence-program. Accessed October 28, 2022.
30. Dagenais S, Russo L, Madsen A, et al. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin Pharmacol Ther. 2022;111(1):77–89.
31. Riskin D. How real-world evidence is shaping the future of healthcare. [Internet]. Forbes; 2021 [cited 2023 Nov 3]. Available from: https://www.forbes.com/sites/forbestechcouncil/2021/11/18/how-real-world-evidence-is-shaping-the-future-of-healthcare/?sh=4519a7627fe3. Accessed June 6, 2022.
32. US Food & Drug Administration. FDA's Sentinel Initiative. 2019. [Internet]. FDA; 2022 May 20 [cited 2023 Nov 3]. Available from: https://www.fda.gov/safety/fdas-sentinel-initiative
33. Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics—guidance for industry [Internet]. FDA; 2022 Jun 06 [cited 2023 Nov 3]. Available from: https://www.fda.gov/media/124795/download
34. US Food and Drug Administration. Advancing real-world evidence program. [Internet]. FDA; 2022 Oct 28 [cited 2023 Nov 3]. Available from: https://www.fda.gov/drugs/developmentresources/advancing-real-world-evidence-program
35. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, Califf RM. Real-world evidence—what is it and what can it tell us. N Engl J Med. 2016;375(23):2293-2297.
36. Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16(5):312-325.
37. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
38. Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;S45-S51.
39. Balani P. Iqvia. [Internet]. informa; 2023 Nov 27 [cited 2023 Nov 3]. Available from: https://turtlmedia.informa.com/story/future-global-pharmaceutical-regulatory-affairs-industry/page/4/1
40. Ribeiro L, Araújo M, Neves J. A review on the use of artificial intelligence in regulatory compliance. In Advances in Intelligent Systems and Computing. 2019; 952:489-498.
41. Wainberg M, et al. Deep learning in drug discovery. Mol Pharm. 2018;15(11):5346-5355.
42. Hazell A, et al. Use of natural language processing in drug development: A systematic review. J Biomed Inform. 2019;95:103208.
43. Jung K, et al. Quality control in pharmaceutical industry: A review. Pharmaceutics. 2021;13(1):16.
44. Li X, et al. Regulatory intelligence and application of natural language processing in drug safety. Drug Saf. 2019;42(2):159-169.
45. Food and Drug Administration (US). 2021. Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program [Internet]. FDA; 2023 May 15 Available from: https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-pilot-program
46. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJ. Artificial intelligence in radiology. Nat Rev Cancer. 2018;18(8):500-510.
47. Thakkar S, Slikker Jr W, Yiannas F, Silva P, Blais B, Chng KR, Tong W. Artificial intelligence and real-world data for drug and food safety–A regulatory science perspective. Regul Toxicol Pharmacol. 2023;140:105388.
48. Cauchon NS, Oghamian S, Hassanpour S, Abernathy M. Innovation in chemistry, manufacturing, and controls-a regulatory perspective from industry. J Pharm Sci. 2019;108(7):2207-2237.
49. Gutierrez L, Cauchon N, Christian T, Giffin M, Abernathy M. The confluence of innovation in therapeutics and regulation: recent CMC considerations. J Pharm Sci. 2020;109:3524–34. doi: 10.1016/j.xphs.2020.09.025.
50. Boisseau P, Loubaton B. Nanomedicine, Nanotechnology in medicine. C R Hebd Seances Acad Sci. 2011;12(7):620-636.
51. Guidance D. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology; 2011.
52. Resnik DB, Tinkle SS. Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials. 2007; 28(4):433-441.
53. Guidance D. Considering whether an FDA-regulated product involves the application of nanotechnology. FDA; 2011.
54. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies - regulatory and scientific considerations. N Engl J Med. 2017;376(11):1101–1103. doi: 10.1056/NEJMp1700786.
55. US Food and Drug Administration (FDA). Personalized Medicine in Oncology: Companion Diagnostics. 2018. [Internet]. FDA [cited 2023 Nov 3]. Available from: https://www.fda.gov/media/110246/download
56. Salmikangas P, Flory E, Reinhardt J. Regulatory challenges for advanced therapy medicinal products. Nat Rev Drug Discov. 2014;13(7):483–484. doi: 10.1038/nrd4344.
57. Woo JH, Kim EC, Kim SM. The current status of breakthrough devices designation in the United States and innovative medical devices designation in Korea for digital health software. Expert Rev Med Devices. 2022;19(3):213-228.
58. Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, Trifirò G. Allergic reactions to COVID-19 vaccines: risk factors, frequency, mechanisms and management. BioDrugs. 2022;36(4):443-458.
59. European Medicines Agency (EMA). Questions and Answers on 3D Printing of Medicinal Products [Internet]. EMA; 2020 [cited 2023 Nov 3]. Available from: https://www.ema.europa.eu/en/documents/other/questions-answers-3d-printing-medicinal-products_en.pdf.
60. Lam J, Kwee BJ, Ricles LM, Sung KE. Development of additive manufacturing-based medical products for clinical translation and marketing. In: Bone Tissue Engineering: Bench to Bedside Using 3D Printing. Cham: Springer International Publishing; 2022.p.267-292.
61. National Academies of Sciences, Engineering, and Medicine. Regulating medicines in a globalized world: the need for increased reliance among regulators; 2020.
62. Bolislis WR, De Lucia ML, Dolz F, Mo R, Nagaoka M, Rodriguez H, Kühler TC. Regulatory agilities in the time of covid-19: overview, trends, and opportunities. Clin Ther. 2021;43(1):124-139.